| CLASS | DRUG/TOX | LP7790-1 |
| COMPONENT | Certolizumab Ab | LP250850-7 |
| PROPERTY | MCnc | LP6827-2 |
| TIME_ASPCT | Pt | LP6960-1 |
| SYSTEM | Ser/Plas | LP7576-4 |
| SCALE_TYP | Qn | LP7753-9 |
| METHOD_TYP | SPR | LP435249-0 |
| parent | Certolizumab | Serum or Plasma | Drug toxicology | LP390572-8 |
| CLASSTYPE | Laboratory class | |
| ORDER_OBS | Observation | |
| EXAMPLE_UNITS | ng/mL | |
| EXAMPLE_UCUM_UNITS | ng/mL | |
| UNITSREQUIRED | N | |
| STATUS | ACTIVE |
| LONG_COMMON_NAME | en-US | Certolizumab Ab [Mass/volume] in Serum or Plasma by SPR |
| LONG_COMMON_NAME | en-US | Certolizumab Ab [Mass/volume] in Serum or Plasma by SPR |
| SHORTNAME | en-US | Certolizumab Ab SerPl SPR-mCnc |
| ConsumerName | en-US | Certolizumab antibody, Blood |
| LONG_COMMON_NAME | fr-FR | Certolizumab anticorps [Masse/Volume] Sérum/Plasma ; Numérique ; SPR |
| LONG_COMMON_NAME | nl-NL | Certolizumab As [massa/volume] in serum of plasma d.m.v. SPR |
LOINC Version: 2.81
FHIR